Report on the Deliberation Results March 8, 2018 Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau Ministry of Health, Labour and Welfare Brand Name Galafold Capsules 123 mg Non-proprietary Name Migalastat Hydrochloride (JAN*) Applicant Amicus Therapeutics, Inc. Date of Application June 28, 2017 Results of Deliberation In its meeting held on March 1, 2018, the First Committee on New Drugs concluded that the product may be approved and that this result should be presented to the Pharmaceutical Affairs Department of the Pharmaceutical Affairs and Food Sanitation Council. The product is not classified as a biological product or a specified biological product. The re-examination period is 10 years. Neither the drug product nor its drug substance is classified as a poisonous drug or a powerful drug. Conditions of Approval 1. The applicant is required to develop and appropriately implement a risk management plan. 2. Because of limited data from Japanese clinical studies, the applicant is required to conduct a post-marketing use-results survey covering all patients treated with the product, to identify the characteristics of the treated patients and to collect safety and efficacy data of the product early so as to take necessary measures for the proper use of the product. *Japanese Accepted Name (modified INN) This English translation of this Japanese review report is intended to serve as reference material made available for the convenience of users. In the event of any inconsistency between the Japanese original and this English translation, the Japanese original shall take precedence. PMDA will not be responsible for any consequence resulting from the use of this reference English translation. Galafold Capsules_Amicus Therapeutics Inc._Review Report Review Report February 15, 2018 Pharmaceuticals and Medical Devices Agency The following are the results of the review of the following pharmaceutical product submitted for marketing approval conducted by the Pharmaceuticals and Medical Devices Agency (PMDA). Brand Name Galafold Capsules 123 mg Non-proprietary Name Migalastat Hydrochloride Applicant Amicus Therapeutics, Inc. Date of Application June 28, 2017 Dosage Form/Strength Capsules, each containing 150 mg of migalastat hydrochloride (123 mg of migalastat). Application Classification Prescription drug, (1) Drug with a new active ingredient Chemical Structure Molecular formula: C6H13NO4·HCl Molecular weight: 199.63 Chemical name: (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol monohydrochloride Items Warranting Special Mention Orphan drug (Drug Designation No. 276 [24 yaku], PSEHB/PED Notification No. 0414-2 dated April 14, 2017, by the Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare) Reviewing Office Office of New Drug I Results of Review On the basis of the data submitted, PMDA has concluded that the product has efficacy in the treatment of Fabry disease with migalastat-responsive GLA mutations, and that the product has acceptable safety in view of its benefits (see Attachment). This English translation of this Japanese review report is intended to serve as reference material made available for the convenience of users. In the event of any inconsistency between the Japanese original and this English translation, the Japanese original shall take precedence. PMDA will not be responsible for any consequence resulting from the use of this reference English translation. 1 Galafold Capsules_Amicus Therapeutics Inc._Review Report As a result of its review, PMDA has concluded that the product may be approved for the indication and dosage and administration shown below, with the following conditions. The safety and the efficacy of the product in patients with renal impairment should be further evaluated. Indication Treatment of Fabry disease with migalastat-responsive GLA mutations Dosage and Administration The usual dosage for patients aged 16 years or older is 123 mg of migalastat orally administered once every other day. Galafold should not be taken at least 2 hours before and 2 hours after a meal. Conditions of Approval 1. The applicant is required to develop and appropriately implement a risk management plan. 2. Because of limited data from Japanese clinical studies, the applicant is required to conduct a post-marketing use-results survey covering all patients treated with the product, to identify the characteristics of the treated patients and to collect safety and efficacy data of the product early so as to take necessary measures for the proper use of the product. 2 Galafold Capsules_Amicus Therapeutics Inc._Review Report Attachment Review Report (1) January 11, 2018 The following is an outline of the data submitted by the applicant and content of the review conducted by the Pharmaceuticals and Medical Devices Agency. Product Submitted for Approval Brand Name Galafold Capsules 123 mg Non-proprietary Name Migalastat Hydrochloride Applicant Amicus Therapeutics, Inc. Date of Application June 28, 2017 Dosage Form/Strength Capsules, each containing 150 mg of migalastat hydrochloride (123 mg of migalastat). Proposed Indication Treatment of Fabry disease with migalastat-responsive GLA mutations Proposed Dosage and Administration The usual dosage for patients aged 16 years or older is 123 mg of migalastat orally administered once every other day at the same time of day. Galafold should be taken in a fasting state, and food should not be consumed at least 2 hours before and 2 hours after taking Galafold. Table of Contents 1. Origin or History of Discovery, Use in Foreign Countries, and Other Information ........................................ 2 2. Data Relating to Quality and Outline of the Review Conducted by PMDA ......................................................... 2 3. Non-clinical Pharmacology and Outline of the Review Conducted by PMDA .................................................... 5 4. Non-clinical Pharmacokinetics and Outline of the Review Conducted by PMDA ............................................. 16 5. Toxicity and Outline of the Review Conducted by PMDA................................................................................. 21 6. Summary of Biopharmaceutic Studies and Associated Analytical Methods, Clinical Pharmacology, and Outline of the Review Conducted by PMDA .................................................................................................. 29 7. Clinical Efficacy and Safety and Outline of the Review Conducted by PMDA ................................................. 48 8. Results of Compliance Assessment Concerning the New Drug Application Data and Conclusion Reached by PMDA ................................................................................................................................................................. 87 9. Overall Evaluation during Preparation of the Review Report (1) ....................................................................... 88 List of Abbreviations See Appendix. 1 Galafold Capsules_Amicus Therapeutics Inc._Review Report 1. Origin or History of Discovery, Use in Foreign Countries, and Other Information Migalastat, developed by Amicus Therapeutics in the U.S., is an analog of the terminal galactose of glycosphingolipid (e.g., globotriaosylceramide [GL-3]) which is a substrate of alpha-galactosidase A (α-Gal A). Migalastat is a pharmacological chaperone that is designed to bind to the mutant forms of α-Gal A. After binding to α-Gal A, migalastat facilitates the transport of α-Gal A to lysosomes and increase α-Gal A activity in lysosomes. Fabry disease is an X-chromosome linked genetic disease and is associated with reduced α-Gal A activity due to mutations in GLA gene encoding α-Gal A which degrades the glycosphingolipids such as GL-3. The accumulation of substrates such as GL-3 in the lysosomes leads to tissue disorders including neurogenic pain, skin symptoms, ophthalmic symptoms, gastrointestinal symptoms, lung symptoms, renal disorders, cardiomyopathy, and cerebrovascular diseases. Fabry disease can be divided into classic and late-onset phenotypes. Classic Fabry disease occurs mainly in men, and patients with the classic phenotype have non- detectable or very low α-Gal A activity and present with renal, cardiac, and cerebrovascular diseases at early stages (The Metabolic and Molecular Bases of Inherited Disease 8th edition. New York; 2001:3733-74). The late-onset phenotype of Fabry disease develops mainly in men with a high residual α-Gal A activity and heterozygous women, and the initial symptoms usually appear in adulthood. The prevalence of Fabry disease is reported to be one per 40,000 to 117,000 persons (The Metabolic and Molecular Bases of Inherited Disease 8th edition. New York. 2001:3733-74; JAMA. 1999;281: 249-54). In Japan, 315 to 1061 patients have a diagnosis of Fabry disease and receive enzyme replacement therapy (ERT).1) Currently, agalsidase beta and agalsidase alfa, products for ERT intravenously administered every 2 weeks, are approved for treatment of Fabry disease: approval was granted for agalsidase beta in January 2004 and for agalsidase alfa in October 2006. The applicant applied for marketing authorization for the product, claiming that the efficacy and safety of the product have been confirmed in studies including global phase III study. Outside Japan, the product was first approved in Europe in May 2016 and has gained approval in 36 countries as of December 2017. In the U.S.,